Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361943676> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4361943676 abstract "<div>Abstract<p><b>Purpose/Experimental Design:</b> Treatment of cerebral tumors and peritumoral brain edema remains a clinical challenge and is associated with high morbidity and mortality. Dexamethasone is an effective drug for treating brain edema, but it is associated with well-documented side effects. Corticorelin acetate (Xerecept) or human corticotrophin-releasing factor (hCRF) is a comparatively new drug and has been evaluated in two orthotopic glioma models (U87 and C6), by a direct comparison with dexamethasone and temozolomide.</p><p><b>Results:</b><i>In vitro</i> combination therapy and monotherapy showed a variable response in 6 different glioma cell lines. <i>In vivo</i> studies showed a dose-dependent effect of hCRF (0.03 and 0.1 mg/kg q12h) on survival of U87 intracranial xenograft–bearing animals [median survival: control – 41 days (95% CI 25–61); “low-hCRF” 74.5 days (95% CI 41–88); “high-hCRF” >130 days (95% CI not reached)]. Dexamethasone treatment had no effect on survival, but significant toxicity was observed. A survival benefit was observed with temozolomide and temozolomide + hCRF-treated animals but with significant temozolomide toxicity. C6-bearing animals showed no survival benefit, but there were similar treatment toxicities. The difference in hCRF treatment response between U87 and C6 intracranial gliomas can be explained by a difference in receptor expression. RT-PCR identified CRF2r mRNA in U87 xenografts; no CRF receptors were identified in C6 xenografts.</p><p><b>Conclusions:</b> hCRF was more effective than either dexamethasone or temozolomide in the treatment of U87 xenografts, and results included improved prognosis with long-term survivors and only mild toxicity. The therapeutic efficacy of hCRF seems to be dependent on tumor hCRF receptor (CRFr) expression. These results support further clinical assessment of the therapeutic efficacy of hCRF and levels of CRFr expression in different human gliomas. <i>Clin Cancer Res; 17(10); 3282–92. ©2011 AACR</i>.</p></div>" @default.
- W4361943676 created "2023-04-05" @default.
- W4361943676 creator A5004111432 @default.
- W4361943676 creator A5012407611 @default.
- W4361943676 creator A5013909433 @default.
- W4361943676 creator A5026192010 @default.
- W4361943676 creator A5029023194 @default.
- W4361943676 creator A5032744554 @default.
- W4361943676 creator A5035464945 @default.
- W4361943676 creator A5061335694 @default.
- W4361943676 creator A5061626942 @default.
- W4361943676 date "2023-03-31" @default.
- W4361943676 modified "2023-09-26" @default.
- W4361943676 title "Data from Comparison of Corticotropin-Releasing Factor, Dexamethasone, and Temozolomide: Treatment Efficacy and Toxicity in U87 and C6 Intracranial Gliomas" @default.
- W4361943676 doi "https://doi.org/10.1158/1078-0432.c.6518385" @default.
- W4361943676 hasPublicationYear "2023" @default.
- W4361943676 type Work @default.
- W4361943676 citedByCount "0" @default.
- W4361943676 crossrefType "posted-content" @default.
- W4361943676 hasAuthorship W4361943676A5004111432 @default.
- W4361943676 hasAuthorship W4361943676A5012407611 @default.
- W4361943676 hasAuthorship W4361943676A5013909433 @default.
- W4361943676 hasAuthorship W4361943676A5026192010 @default.
- W4361943676 hasAuthorship W4361943676A5029023194 @default.
- W4361943676 hasAuthorship W4361943676A5032744554 @default.
- W4361943676 hasAuthorship W4361943676A5035464945 @default.
- W4361943676 hasAuthorship W4361943676A5061335694 @default.
- W4361943676 hasAuthorship W4361943676A5061626942 @default.
- W4361943676 hasConcept C126322002 @default.
- W4361943676 hasConcept C128473837 @default.
- W4361943676 hasConcept C143998085 @default.
- W4361943676 hasConcept C150903083 @default.
- W4361943676 hasConcept C207001950 @default.
- W4361943676 hasConcept C2777389519 @default.
- W4361943676 hasConcept C2778227246 @default.
- W4361943676 hasConcept C2780401358 @default.
- W4361943676 hasConcept C29730261 @default.
- W4361943676 hasConcept C502942594 @default.
- W4361943676 hasConcept C71924100 @default.
- W4361943676 hasConcept C86803240 @default.
- W4361943676 hasConcept C98274493 @default.
- W4361943676 hasConceptScore W4361943676C126322002 @default.
- W4361943676 hasConceptScore W4361943676C128473837 @default.
- W4361943676 hasConceptScore W4361943676C143998085 @default.
- W4361943676 hasConceptScore W4361943676C150903083 @default.
- W4361943676 hasConceptScore W4361943676C207001950 @default.
- W4361943676 hasConceptScore W4361943676C2777389519 @default.
- W4361943676 hasConceptScore W4361943676C2778227246 @default.
- W4361943676 hasConceptScore W4361943676C2780401358 @default.
- W4361943676 hasConceptScore W4361943676C29730261 @default.
- W4361943676 hasConceptScore W4361943676C502942594 @default.
- W4361943676 hasConceptScore W4361943676C71924100 @default.
- W4361943676 hasConceptScore W4361943676C86803240 @default.
- W4361943676 hasConceptScore W4361943676C98274493 @default.
- W4361943676 hasLocation W43619436761 @default.
- W4361943676 hasOpenAccess W4361943676 @default.
- W4361943676 hasPrimaryLocation W43619436761 @default.
- W4361943676 hasRelatedWork W2026514919 @default.
- W4361943676 hasRelatedWork W2057540983 @default.
- W4361943676 hasRelatedWork W2060629072 @default.
- W4361943676 hasRelatedWork W2079763637 @default.
- W4361943676 hasRelatedWork W2347699387 @default.
- W4361943676 hasRelatedWork W2888674289 @default.
- W4361943676 hasRelatedWork W3043435845 @default.
- W4361943676 hasRelatedWork W3085891736 @default.
- W4361943676 hasRelatedWork W4205155257 @default.
- W4361943676 hasRelatedWork W4311687976 @default.
- W4361943676 isParatext "false" @default.
- W4361943676 isRetracted "false" @default.
- W4361943676 workType "article" @default.